{
 "as_of": "2026-11-06",
 "cmr": "se-cm-kg/XSTO/SE0009414576",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# Oncopeptides AB (Nasdaq Stockholm: SE0009414576) — research page\n\nAs of 2026-11-06 · se-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is Oncopeptides AB, listed on Nasdaq Stockholm under the ticker SE0009414576, with ISIN SE0009414576 and LEI 549300J9WWQ5CBYQ1M77. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 43 filings in the window 2025-11-06 to 2026-11-06, on 39 filing days. The median gap between filing days is 5.5 days. The latest filing is dated 2026-11-05 and is an Interim report (Q1 and Q3), 1 day before the record date of 2026-11-06. The exchange median cadence gap is 9.5 days across 398 issuers, and the exchange median filings count is 30.0. The exchange median latency is 7.0 days. The sector median is not on the record.\n\n## Auditor\n\nThe auditor, its location and any auditor changes are not on the record, as this register has no lifecycle type map yet.\n\n## Events and halts\n\nThe listing, delisting, name change, domicile change and segment move lines are not on the record, as this register has no lifecycle type map yet. The halt flag shows listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable under acm-68000/se/mifid-ii-product-governance/r1, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The chapter is as of 2026-11-04.\n\n## Coverage\n\nThe issuer's investor-relations page names 3 research houses: ABG Sundal Collier, DNB Carnegie and Redeye.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe market's vintage is not sealed. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record began is not on the record.\n\n## Sources\n\n7 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://firds.esma.europa.eu/firds/ (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.se-cm-kg.ai/events/XSTO/SE0009414576 (the disclosure lines)\n- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)\n- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://oncopeptides.com/investors/the-share/ (coverage)\n- https://mcp.se-cm-kg.ai/record/XSTO/SE0009414576 (the record)\n",
 "market": "SE",
 "node": "se-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": null,
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "the SE vintage is not sealed; the record is the live record as of 2026-11-06",
   "record_version": 1,
   "sealed": false
  },
  "auditor": {
   "auditor": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "SE",
    "state": "not_on_record"
   },
   "changes": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "cmr": "se-cm-kg/XSTO/SE0009414576",
  "coverage": {
   "count": 3,
   "houses": [
    {
     "analyst": "Georg Tigalonov-Bjerke",
     "house": "ABG Sundal Collier",
     "read_by": "issuer IR page, fetched by this rail; house names read through Mistral (mistral-small-latest), each then found on the page",
     "read_date": "2026-11-12",
     "source": "https://oncopeptides.com/investors/the-share/",
     "state": "sourced"
    },
    {
     "analyst": "Erik Hultgård",
     "house": "DNB Carnegie",
     "read_by": "issuer IR page, fetched by this rail; house names read through Mistral (mistral-small-latest), each then found on the page",
     "read_date": "2026-11-12",
     "source": "https://oncopeptides.com/investors/the-share/",
     "state": "sourced"
    },
    {
     "analyst": "Richard Ramanius",
     "house": "Redeye",
     "read_by": "issuer IR page, fetched by this rail; house names read through Mistral (mistral-small-latest), each then found on the page",
     "read_date": "2026-11-12",
     "source": "https://oncopeptides.com/investors/the-share/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://oncopeptides.com/investors/the-share/",
     "result": "read: 3 of 6 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-12",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 398,
     "median_cadence_gap_days": 9.5,
     "median_filings": 30,
     "median_latency_days": 7,
     "name": "Nasdaq Stockholm"
    },
    "sector": {
     "market": "SE",
     "state": "not_on_record"
    }
   },
   "by_type": {
    "Annual Financial Report": 1,
    "Decisions of general meeting": 1,
    "Financial Statement Release": 1,
    "Half Year financial report": 1,
    "Inside information": 7,
    "Interim report (Q1 and Q3)": 2,
    "Investor News": 23,
    "Notice to general meeting": 1,
    "Other information disclosed according to the rules of the Exchange": 3,
    "Total number of voting rights and capital": 3
   },
   "cadence_median_gap_days": 5.5,
   "filing_days": 39,
   "filings": 43,
   "latency_days": 1,
   "latest": [
    {
     "category": "Interim report (Q1 and Q3)",
     "date": "2026-11-05",
     "source": "https://view.news.eu.nasdaq.com/view?id=bddc3c8fcc8d7dbbe69130451b9527e01&lang=en&src=listed",
     "title": "Oncopeptides publishes Q3 report 2026",
     "type": "Interim report (Q1 and Q3)"
    },
    {
     "category": "Investor News",
     "date": "2026-11-04",
     "source": "https://view.news.eu.nasdaq.com/view?id=b9a620b22d989c46e52c88ed615b9af69&lang=en&src=listed",
     "title": "New European real-world evidence supporting Pepaxti in heavily pretreated multiple myeloma to be presented at ASH 2026",
     "type": "Investor News"
    },
    {
     "category": "Total number of voting rights and capital",
     "date": "2026-10-30",
     "source": "https://view.news.eu.nasdaq.com/view?id=b103da01f4654d2b3f70c53fe35803eb4&lang=en&src=listed",
     "title": "Number of shares and votes in Oncopeptides",
     "type": "Total number of voting rights and capital"
    },
    {
     "category": "Investor News",
     "date": "2026-10-29",
     "source": "https://view.news.eu.nasdaq.com/view?id=b60832de17281702b4e872066cf4634e6&lang=en&src=listed",
     "title": "Invitation to presentation of the Q3 report 2026",
     "type": "Investor News"
    },
    {
     "category": "Inside information",
     "date": "2026-10-13",
     "source": "https://view.news.eu.nasdaq.com/view?id=bb511ee3e03a1f61f4f40883bba422c3b&lang=en&src=listed",
     "title": "Oncopeptides intends to carry out a directed share issue of approximately SEK 100 million",
     "type": "Inside information"
    }
   ],
   "latest_filing_date": "2026-11-05",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.se-cm-kg.ai/events/XSTO/SE0009414576",
   "window": {
    "from": "2025-11-06",
    "to": "2026-11-06"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Nasdaq Stockholm"
   },
   "isin": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0009414576"
   },
   "jurisdiction": {
    "market": "SE",
    "state": "not_on_record"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-09",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN SE0009414576)",
    "state": "sourced",
    "value": "549300J9WWQ5CBYQ1M77"
   },
   "name": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "Oncopeptides AB"
   },
   "sector": {
    "market": "SE",
    "state": "not_on_record"
   },
   "security_type": {
    "market": "SE",
    "state": "not_on_record"
   },
   "segment": {
    "market": "SE",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0009414576"
   },
   "website": {
    "market": "SE",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "domicile_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "listing": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "name_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "segment_move": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "market": "SE",
  "node": "se-cm-kg",
  "numbers_hash": "sha256:5b8f2117353617303c92b30570e92ddd98741996d29f8cd4bfc0a87c82acdfba",
  "open_research": {
   "read_date": "2026-11-12",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://se.eu-cm-kg.ai/book/aio.json",
    "door": "https://se.eu-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/se/mifid-ii-product-governance/r1",
   "section": "se.aio.v5"
  },
  "record": {
   "as_of": "2026-11-06",
   "url": "https://mcp.se-cm-kg.ai/record/XSTO/SE0009414576",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-09",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:5b8f2117353617303c92b30570e92ddd98741996d29f8cd4bfc0a87c82acdfba",
 "path": "/se/XSTO/SE0009414576",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is Oncopeptides AB, listed on Nasdaq Stockholm under the ticker SE0009414576, with ISIN SE0009414576 and LEI 549300J9WWQ5CBYQ1M77. Its security type, segment, sector and jurisdiction are not on the record. Its listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 43 filings in the window 2025-11-06 to 2026-11-06, on 39 filing days. The median gap between filing days is 5.5 days. The latest filing is dated 2026-11-05 and is an Interim report (Q1 and Q3), 1 day before the record date of 2026-11-06. The exchange median cadence gap is 9.5 days across 398 issuers, and the exchange median filings count is 30.0. The exchange median latency is 7.0 days. The sector median is not on the record.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor, its location and any auditor changes are not on the record, as this register has no lifecycle type map yet.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The listing, delisting, name change, domicile change and segment move lines are not on the record, as this register has no lifecycle type map yet. The halt flag shows listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable under acm-68000/se/mifid-ii-product-governance/r1, because the chapter's orderability section carries no client categories and so the outcome cannot name its client category. The chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's investor-relations page names 3 research houses: ABG Sundal Collier, DNB Carnegie and Redeye.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The market's vintage is not sealed. No issuer years are sealed, the market's earliest sealed date is not on the record, and the live record began is not on the record.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "7 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://firds.esma.europa.eu/firds/"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.se-cm-kg.ai/events/XSTO/SE0009414576"
  },
  {
   "for": "the halt flag",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation"
  },
  {
   "for": "the orderability chapter",
   "source": "https://se.eu-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://oncopeptides.com/investors/the-share/"
  },
  {
   "for": "the record",
   "source": "https://mcp.se-cm-kg.ai/record/XSTO/SE0009414576"
  }
 ],
 "title": "Oncopeptides AB (SE0009414576) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}